All lobbying filings

GENENTECH, INC

GENENTECH, INC filed a Q1 amendment for GENENTECH INC on April 20, 2026.

Lobbying for GENENTECH INC

All filings by GENENTECH, INC · Everything GENENTECH INC has reported

Filing · LD-2 quarterly report Q1 amendment

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$3,780,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 8

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 10

Pharmacy

Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program

Manufacturing

Issues related to pharmaceutical supply chains Issues related to reporting on location of origin of pharmaceutical products Issues related to drug shortages Issues related to pharmaceutical manufacturing

Immigration

Issues relating to limits and restrictions on the immigration of high skilled workers Issues relating to the immigration of medical researchers

Budget/Appropriations

Issues related to FDA and HHS program funding for the FY25 Labor, HHS, Education and Related Agencies, and FY25 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicineS Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance Deficit reduction, reconciliation

Intellectual property and process patent issues Patent litigation reforms PTAB and IPR processes Section 101 Reform Domestic and international compulsory licensing issues March-in Rights

Health Issues

Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. Issues related to healthcare legislation Patient access to Part B medicines Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness. Issues related to access to drugs for minority communities Issues related to healthcare education and screening

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI

Taxation/Internal Revenue Code

Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives

Trade (domestic/foreign)

Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver Issues related to compulsory licensing of foreign patents Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)

Medical/Disease Research/Clinical Labs

Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development Issues related to research and product development Issues related to drug development including PDUFA

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.